Recently, SIGNDO Biotechnology (Suzhou) Co., Ltd. (referred to as "SIGNDO Biotech") announced the completion of a Pre-A round of financing, raising tens of millions of RMB. This round of financing will help the company rapidly advance the clinical trial of its first drug pipeline for tumor-targeted fluorescent contrast agents, continue the development of other pipelines, and support research collaborations. The financing round was exclusively led by Gaobai Captial with continued investment from existing shareholder STONE PINE Captial.

01 The leader of Tumor-Targeted Fluorescent Contrast Agents

SIGNDO Biotech was established in Suzhou Industrial Park in February 2021, focusing on the R&D and industrialization of tumor-targeted fluorescent contrast agents, with the goal of "Illuminate cancer, Precision surgery." SIGNDO Biotech has built the RTTFC® technology platform and developed various Fluorescence-Drug Conjugates (FDC) for fluorescence-guided surgery. FDCs can "target/label tumors," "intraoperatively image," and "precisely determine positive margins" based on specific markers of different solid tumors. The products offer advantages such as "high sensitivity, strong specificity, and excellent TBR (tumor-to-background ratio)," assisting surgeons in clearly visualizing tumor boundaries, determining positive margins, and locating metastatic lymph nodes. SIGNDO Biotech is committed to become the leader of tumor-targeted fluorescent contrast agents. Currently, the company's first pipeline DGPR1008 has completed preclinical studies and will soon apply for IND.

02 Milestone Events

1. Advancing the IND application for DGPR1008, the company's first drug pipeline, followed by the initiation of a Phase I clinical trial.

2. Building a preclinical product portfolio targeting multiple cancers, including several First-in-Class and Best-in-Class projects. The company's proprietary RTTFC® technology platform aims to accelerate and streamline the discovery process of targeted fluorescent imaging agents for various tumors.

3. Integrating production, academia, research, and medicine, SIGNDO Biotech collaborates closely with several top-tier hospitals in China to achieve the translation of scientific research into clinical practice. In 2023, the company completed an investigator-initiated trial in China, demonstrating significant clinical benefits.

03 About RTTFC® 

Real-Time Targeted Fluorescent Conjugate (RTTFC®) is SIGNDO Biotech proprietary technology platform designed to enhance the discovery efficiency of targeted fluorescent contrast agent candidate compounds. From initial screening to obtaining candidate compounds with biodistribution data, the development cycle on the RTTFC® platform does not exceed eight months. The platform builds on SIGNDO Bioteth's robust R&D capabilities, developing Fluorescence-Drug Conjugates (FDC) for intraoperative molecular imaging of various solid tumors. It utilizes a comprehensive toolkit of targeting groups and linker libraries, enabling the rapid conversion of compounds with strong targeting properties, high affinity, and a favorable tumor-to-background ratio into Pre-Clinical Candidates (PCCs).

04 They Said

Ms. Jing Zhao, Founder and CEO of SIGNDO Biotech, said:

" Going from clinic to clinic has always been the lifeline of SIGNDO Biotech. We focus closely on the unmet clinical needs of patients, with the goal of 'Illuminate cancer, Precision surgery'. Our primary considerations are, first, clinical needs and clinical value; second, while innovative drugs are a highly competitive field, our products require a combination of drug development pathways, device usage logic, and diagnostic clinical thinking. We continuously innovate to consolidate our leading position and differentiation advantages, delivering value to patients while meeting market potential and returns."

Mr. Feng Dang, STONE PINE Captial said:

"In recent years, targeted therapies have improved cancer patient survival rates, but surgical resection remains the preferred treatment for most primary cancers. Precision and intelligence in surgical procedures are the trends of the future, and molecular imaging is a revolutionary technology for precision surgery. While existing technologies can assist in identifying larger lesions pre- and postoperatively, they cannot precisely locate tumors in real-time during surgery or accurately determine surgical margins due to technical limitations. SIGNDO Bio's development pipelines can accurately visualize tumors, locate metastatic lymph nodes, and determine positive margins intraoperatively. SIGNDO Bio's core technologies, extensive product pipelines, excellent product performance, and innovative technical strength have been widely recognized, heralding a new era of near-infrared targeted fluorescent imaging. We look forward to more exciting developments from SIGNDO Biotech in the future."

05 Moving Forward Unceasingly

Finally, we express our deep gratitude to Gaobai captial Limited for leading this investment round and to our existing shareholder STONE PINE Entrepreneurship Investment Partnership Enterprise (Limited Partnership) for their continued support. We will continue to work tirelessly to bring our independently developed tumor-targeted fluorescent imaging agents to clinical use as soon as possible, truly achieving ' go from clinic to clinic,' benefiting more cancer patients.